

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on June 2, 2008.



Sherry Loke

SUBMISSION OF SEQUENCE LISTING
UNDER 37 CFR §§1.821-1.825
Patent Application
Docket No. ARS-117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Stacey Nee MacFarlane
Art Unit : 1649
Applicants : Georg Feger, Ursula Boschert, Yves Sagot, Ruben Papoian
Serial No. : 10/550,775
Filed : September 27, 2005
Conf. No. : 1797
For : Use of Clusterin for the Treatment and/or Prevention of Peripheral
Neurological Diseases

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §§1.821-1.825

Sir:

Transmitted herewith is a replacement Sequence Listing Under 37 CFR §§1.821 through 1.825 for the above-identified patent application. Also enclosed is an Amendment Under 37 C.F.R. § 1.111. In an Office Action dated January 31, 2008, the Examiner indicated that the subject application failed to meet the requirements of 37 CFR §§1.821-1.825.

The Sequence Listing is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. 19-0065.

Respectfully submitted,

/FRANKCEISENSCHENK/

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Sequence listing on paper and computer readable format containing the same information; Amendment Under 37 C.F.R. § 1.111